Skip to main content
OpenTrials

Clinical trial condition

Chronic Spontaneous Urticaria

Explore clinical trials studying Chronic Spontaneous Urticaria. Study availability and eligibility vary by location and protocol.

69 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Chronic Spontaneous Urticaria trial results

Completed

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

NCT04109313

Conditions
Chronic Disease, Chronic Spontaneous Urticaria, Chronic Urticaria, +10 more
Locations
  • Novartis Investigative Site Litchfield Park, Arizona, United States
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Mission Viejo, California, United States
  • Novartis Investigative Site San Diego, California, United States
View all 69 locations
View Trial Details
Completed

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369

Conditions
Chronic Disease, Chronic Spontaneous Urticaria, Chronic Urticaria, +10 more
Locations
  • Novartis Investigative Site Gilbert, Arizona, United States
  • Novartis Investigative Site Litchfield Park, Arizona, United States
  • Novartis Investigative Site Scottsdale, Arizona, United States
  • Novartis Investigative Site Little Rock, Arkansas, United States
View all 161 locations
View Trial Details
Completed

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794

Conditions
Chronic Disease, Chronic Spontaneous Urticaria, Chronic Urticaria, +10 more
Locations
  • Clinical Research Center of Alabama Birmingham, Alabama, United States
  • Arizona Allergy & Immunology Research Gilbert, Arizona, United States
  • Sarasota Clinical Research Sarasota, Florida, United States
  • ForCare Clinical Research Tampa, Florida, United States
View all 14 locations
View Trial Details
Completed

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

NCT03926611

Conditions
Chronic Disease, Chronic Spontaneous Urticaria, Chronic Urticaria, +10 more
Locations
  • Novartis Investigative Site Litchfield Park, Arizona, United States
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Mission Viejo, California, United States
  • Novartis Investigative Site San Diego, California, United States
View all 82 locations
View Trial Details
Completed

Dupilumab in Chronic Spontaneous Urticaria

NCT03749135

Conditions
Angioedema, Cardiovascular Diseases, Chronic Disease, +17 more
Locations
  • Universitätsklinikum Giessen und Marburg Marburg, Hesse, Germany
  • Hautklinik Universitätsklinikum Münster Münster, NRW, Germany, Germany
  • Hautklinik der Universitätsmedizin Mainz Clinical Research Center Mainz, Rheinland-Pfalz, Germany, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden, Saxony, Germany
View Trial Details
Completed

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218

Conditions
Bronchial Diseases, Bronchiolitis, Bronchiolitis Obliterans, +20 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Scottsdale, Arizona, United States
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Sarasota, Florida, United States
View all 67 locations
View Trial Details
Completed

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332

Conditions
Bronchial Diseases, Bronchiolitis, Bronchiolitis Obliterans, +20 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Scottsdale, Arizona, United States
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Huntington Beach, California, United States
View all 82 locations
View Trial Details
Completed

Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

NCT03328897

Conditions
Chronic Disease, Chronic Spontaneous Urticaria, Chronic Urticaria, +10 more
Locations
  • Novartis Investigative Site Beijing, Beijing Municipality, China
  • Novartis Investigative Site Fuzhou, Fujian, China
  • Novartis Investigative Site Guangzhou, Guangdong, China
  • Novartis Investigative Site Nanning, Guangxi, China
View all 27 locations
View Trial Details

Related conditions